Celcuity Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biotech developing gedatolisib, a drug aimed at blocking cancer-driving cell signals to treat advanced breast and prostate cancer. Founded in 2012 by Brian Sullivan and Lance Laing, the company first built CELsignia, a tool that reads living tumor cells, before pivoting to drug development. Its name blends "cell" and "acuity" — a nod to the sharp, precise view the founders wanted of a tumor's inner workings.
Bought 170.1K
Granted 1.0K
Granted 1.5K
Granted 1.5K · Sold 60.0K
Granted 1.8K
Granted 21.5K · Sold 20.0K
Granted 1.5K
Granted 1.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +3 co-filers10% owner · 4 transactions | — | 15.66M | — | 170.1K | — |
| Sullivan Brian F.Chief Executive Officer, Director · 1 transaction | +3.5% | 3.12M | — | — | — |
| Laing Lance G.Chief Science Officer, Director · 1 transaction | +0.1% | 1.25M | 1.0K | — | — |
| Nigon RichardDirector · 5 transactions | -20.3% | 80.6K | 1.5K | — | — |
| Dalvey DavidDirector · 4 transactions | -46.8% | 66.5K | 1.5K | — | 60.0K |
| Furcht LeoDirector · 2 transactions | +16.6% | 12.5K | 1.8K | — | — |
| Buller Richard EDirector · 22 transactions | +6% | 9.3K | 21.5K | — | 20.0K |
| Murphy Polly A.Director · 1 transaction | +30.6% | 6.5K | 1.5K | — | — |
| Romp Charles RDirector · 2 transactions | — | 1.7K | 1.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +90.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.